# REVIVO Biosystems Pte.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revivo-biosystems-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.revivobio.com
- Total disclosed funding: $2M
- Latest round: Seed (Feb 21, 2023)
- Investors on record: 3

## About

Based in Singapore, and founded in 2019 by Bert Grobben, Massimo Alberti, Sriram Gopu, and Zhiping Wang, REVIVO Biosystems Pte. Ltd develops technology that uses a realistic 4D model of human skin for the testing of chemical, cosmetic, and pharmaceutical research labs. In November 2021, REVIVO Biosystems Pte. Ltd raised an undisclosed amount of venture funding from Evonik Venture Capital. Mr. Massimo Alberti is the CEO of REVIVO Biosystems Pte. Ltd.

REVIVO Biosystems provides technology and services for in vitro and ex vivo testing of chemicals, cosmetic formulations, ingredients, and therapeutics. The company also offers a platform that automates the testing procedure ex vivo and in vitro screening on epithelial tissue models. In addition, REVIVO provides proprietary 4D human skin models with multiple properties, including barrier property, subcutaneous blood flow, full-thickness & morphology, and viable skin for up to 21 days. The company offers an alternative to animal testing, which is cost-efficient, reliable, and quicker. The company’s major customers are cosmetic manufacturers, pharma and biotech, academic labs, CROs, and ingredient providers. 

REVIVO Biosystems Pte. Ltd plans to use its proceeds from November 2021 funding to support the development and commercialization of a realistic 4D model of human skin that provides an alternative to animal testing.

## Funding rounds

- Seed, Feb 21, 2023, $2M — SGInnovate, Evonik Venture Capital, B7 Capital

## Investors

- SGInnovate (https://capitalatlas.ai/funds/sginnovate) — Seed
- Evonik Venture Capital (https://capitalatlas.ai/funds/evonik-venture-capital) — Seed
- B7 Capital — Seed